NASDAQ:DOVA Dova Pharmaceuticals (DOVA) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free DOVA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$28.04▼$28.0450-Day Range$28.04▼$28.0452-Week Range$5.62▼$28.54Volume35,036 shsAverage Volume499,313 shsMarket Capitalization$807.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Dova Pharmaceuticals alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Dova Pharmaceuticals Stock (NASDAQ:DOVA)Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… DOVA Stock News HeadlinesMarch 7, 2024 | uk.finance.yahoo.comAnalysis of Co-promotion and Co-marketing Deals in Pharmaceuticals and Biotechnology Signed During 2016-2024August 22, 2023 | bizjournals.comFulcrum swings back up after FDA lifts clinical holdMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.May 15, 2023 | technews.tmcnet.comFulcrum Therapeutics Appoints Alex C. Sapir Chief Executive OfficerMarch 29, 2023 | marketwatch.comImmune Thrombocytopenia Market 2023 Size to reach USD 3.33 Billion by 2026 With A 0.54% CAGRMarch 21, 2023 | marketwatch.comWith A 0.54% CAGR, Immune Thrombocytopenia Market 2023 Size Will Reach USD 3.33 Billion by 2026February 27, 2023 | marketwatch.comLatest Research on Chemotherapy Induced Thrombocytopenia Drugs Market Report 2023-2029February 19, 2023 | marketwatch.comGlobal Immune Thrombocytopenia Treatment Market Size To Grow On The Basis Of Refined Innovation From 2023-2030 By VMReportsMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.September 20, 2022 | finance.yahoo.comPasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of DirectorsSeptember 14, 2022 | investing.comTethys Oil AB (TETY)August 11, 2022 | fool.comMolina Healthcare (NYSE: MOH)July 23, 2022 | uk.news.yahoo.comUK watchdog fines Pfizer, Flynn Pharma $84 million for overcharging NHSJuly 19, 2022 | marketwatch.comGlobal Immune Thrombocytopenia Market to Rise at 0.54% CAGR from 2019-2026June 9, 2022 | investing.comDOVA_old Historical DataApril 30, 2022 | uk.finance.yahoo.com'This is not pressure' - Passionate Parker issues rallying cry ahead of huge Blackburn clashApril 30, 2022 | reuters.comUkraine Holocaust survivors find shelter in IsraelMarch 24, 2022 | marketwatch.comImmune Thrombocytopenia (ITP) Market Research Update, Size Estimation, Future Scope, Revenue Opportunities and Regional Forecast to 2028November 9, 2021 | benzinga.comVerona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateSeptember 2, 2021 | marketwatch.comAdvent, GIC Affiliate Launch $8.1 Bln Takeover Bid for Sweden's SobiSee More Headlines Receive DOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dova Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2019Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:DOVA CUSIPN/A CIK1685071 Webwww.dova.com Phone919-748-5975FaxN/AEmployees115Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,280,000.00 Net Margins-544.09% Pretax MarginN/A Return on Equity-101.60% Return on Assets-67.21% Debt Debt-to-Equity Ratio0.41 Current Ratio5.64 Quick Ratio5.37 Sales & Book Value Annual Sales$10.35 million Price / Sales78.02 Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book10.35Miscellaneous Outstanding Shares28,800,000Free FloatN/AMarket Cap$807.55 million OptionableOptionable Beta2.74 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. David S. Zaccardelli (Age 54)Pres & CEO Mr. Mark W. Hahn (Age 56)CFO & Sec. Mr. Kevin Laliberte (Age 41)Sr. VP of Product Devel. Mr. Jason LevineVP of MarketingMr. Ilija ZlatarHead of U.S. SalesKey CompetitorsEvolusNASDAQ:EOLSTango TherapeuticsNASDAQ:TNGXPureTech HealthNASDAQ:PRTCPraxis Precision MedicinesNASDAQ:PRAXTyra BiosciencesNASDAQ:TYRAView All Competitors DOVA Stock Analysis - Frequently Asked Questions How were Dova Pharmaceuticals' earnings last quarter? Dova Pharmaceuticals Inc (NASDAQ:DOVA) announced its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by $0.03. The business had revenue of $3.52 million for the quarter, compared to the consensus estimate of $5.63 million. Dova Pharmaceuticals had a negative net margin of 544.09% and a negative trailing twelve-month return on equity of 101.60%. What other stocks do shareholders of Dova Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dova Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Aldeyra Therapeutics (ALDX), Tesaro (TSRO), Allena Pharmaceuticals (ALNA), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Ardelyx (ARDX), Fate Therapeutics (FATE), Galectin Therapeutics (GALT) and Heron Therapeutics (HRTX). When did Dova Pharmaceuticals IPO? Dova Pharmaceuticals (DOVA) raised $66 million in an IPO on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO. This page (NASDAQ:DOVA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dova Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.